Conmed (CNMD) Common Equity (2010 - 2026)

Conmed (CNMD) has 17 years of Common Equity data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 4.1% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 4.1% YoY), and the FY2025 full-year result was $1.0 billion, up 7.31% from the prior year.
• Common Equity for Q1 2026 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.0 billion in Q4 2025 and bottomed at $673.0 million in Q2 2022.
• The 5-year median for Common Equity is $854.7 million (2024), against an average of $868.2 million.
• The widest annual swing landed in 2022, when Common Equity decreased 9.61%; it then advanced 17.17% in 2024.
• A 5-year view of Common Equity shows it stood at $745.5 million in 2022, then increased by 11.89% to $834.2 million in 2023, then advanced by 15.4% to $962.7 million in 2024, then climbed by 7.31% to $1.0 billion in 2025, then decreased by 1.49% to $1.0 billion in 2026.
• The last three Common Equity figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.

Peer Comparison